title: Analysis of G(1)/S checkpoint regulators in metastatic melanoma.
abstract: We have analyzed the expression of the CDKN1A (p21(CIP1)), CDKN1B (p27(Kip1)), TP53, RB1 and MDM2 proteins and tumor cell proliferation by immunohistochemical staining in 59 cases of metastatic melanoma. The genomic status of the CDKN2A (INK4-ARF, p16/p14(ARF)), CDKN2B (p15) and CDKN2C (p18) genes was determined by PCR-SSCP (single-strand conformation polymorphism) in 46 of these cases. These results were correlated with various clinico-pathological parameters, including the outcome of combined chemoimmunotherapy. We found positive correlations between the expression of CDKN1A and MDM2 (r = 0.5063, P = 0.001), between the expression of CDKN1B and RB1 (r = 0.5026, P = 0.001), and between RB1 expression and tumor cell proliferation (0.5564, P<0.001). Two mutations in the CDKN2A (p16) gene were detected, including a novel base change AAC-->ATC (Asn to Ile) at codon 71, that also changes the codon 85 of the alternative reading frame gene p14(ARF) from CAA to CAT (Gln to His). Homozygous deletion at exon 2 of the CDKN2A (INK4-ARF) gene was detected in six cases. In seven cases, the 540C-->G polymorphism in the 3'UTR of the CDKN2A (p16) gene was found in linkage disequilibrium with the 74C-->A polymorphism in intron 1 of the CDKN2B gene (P < 0.0001). These cases had significantly lower expression of the TP53 protein (P = 0.0032). Both 540C-->G and 580C-->T polymorphisms in the 3'UTR of the CDKN2A (p16) gene were associated with significantly shorter progression time from primary to metastatic disease (P = 0.0071). We conclude, that although none of the analyzed cell cycle regulators could be singled out as a major prognostic factor, G(1)/S checkpoint abnormalities remain one of the most significant factors in the development of malignant melanoma.
authors.affiliation: Department of Dermatology, University of Turku, Finland. ilasau@utu.fi
authors.forename: I
authors.initials: I
authors.lastname: Sauroja
authors.forename: J
authors.initials: J
authors.lastname: Smeds
authors.forename: T
authors.initials: T
authors.lastname: Vlaykova
authors.forename: R
authors.initials: R
authors.lastname: Kumar
authors.forename: L
authors.initials: L
authors.lastname: Talve
authors.forename: M
authors.initials: M
authors.lastname: Hahka-Kemppinen
authors.forename: K
authors.initials: K
authors.lastname: Punnonen
authors.forename: C T
authors.initials: CT
authors.lastname: Jansèn
authors.forename: K
authors.initials: K
authors.lastname: Hemminki
authors.forename: S
authors.initials: S
authors.lastname: Pyrhönen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D016193:G1 Phase; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000737:chemistry / Q000188:drug therapy / Q000473:pathology* / Q000556:secondary*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D016196:S Phase; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D008130:Lomustine; D003606:Dacarbazine